Discovery of an orally active non-peptide fibrinogen receptor antagonist

Journal of Medicinal Chemistry

Volumn 39, Issue 11, 1996, Pages 2118-2122

  Stilz, Hans Ulrich ^a   Jablonka, Bernd ^a   Just, Melitta ^a   Knolle, Jochen ^a   Paulus, Erich Friedrich ^a   Zoller, Gerhard ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST; S 1197; S 1762; S 5740; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CONFORMATION; DRUG FORMULATION; DRUG POTENCY; DRUG SYNTHESIS; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOEMBOLISM;

ADENOSINE DIPHOSPHATE; ANIMALS; BLOOD PLATELETS; CARBOXYLIC ACIDS; DOGS; HUMANS; MOLECULAR STRUCTURE; OLIGOPEPTIDES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0029945361     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960210f     Document Type: Article

References (44)

1. Fitzgerald, D. J.; Roy, L.; Catella, F.; Fitzgerald, G. A. Platelet activation in unstable coronary disease. N. Engl. J. Med. 1986, 315, 983-989.
2. Fuster, V.; Steele, P. M.; Chesebro, J. H. Role of platelets and thrombosis in coronary atherosclerotic disease and sudden death. J. Am. Coll. Cardiol. 1985, 5, 175B-184B.
3. Harrison, M. J. G. Role of platelets and antiplatelet agents in cerebrovascular disease.: Clues from trials. Circulation 1990, 81 (suppl. I), I-20-I-21.
4. Davies, M. J.; Thomas, A. C. Plaques fissuring - the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br. Heart J. 1985, 53, 363-373.
5. For recent reviews, see: (a) Cook, N. S.; Kottirsch, G.; Zerwes, H.-G. Platelet glycoprotein IIb/IIIa antagonists. Drugs Future 1994, 19, 135-159. (b) Weller, T.; Alig, L.; Hürzeler Müller, M.; Kouns, W. C.; Steiner, B. Fibrinogen receptor antagonists - a novel class of promising antithrombotics. Drugs Future 1994, 19, 461-476. (c) Austel, V.; Himmelsbach, F.; Müller, T. Non-peptidic fibrinogen receptor antagonists. Drugs Future 1994, 19, 757-764. (d) Lefkovits, J.; Plow, E. F.; Topol, E. J. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N. Engl. J. Med. 1995, 332, 1553-1559.
6. For recent reviews, see: (a) Cook, N. S.; Kottirsch, G.; Zerwes, H.-G. Platelet glycoprotein IIb/IIIa antagonists. Drugs Future 1994, 19, 135-159. (b) Weller, T.; Alig, L.; Hürzeler Müller, M.; Kouns, W. C.; Steiner, B. Fibrinogen receptor antagonists - a novel class of promising antithrombotics. Drugs Future 1994, 19, 461-476. (c) Austel, V.; Himmelsbach, F.; Müller, T. Non-peptidic fibrinogen receptor antagonists. Drugs Future 1994, 19, 757-764. (d) Lefkovits, J.; Plow, E. F.; Topol, E. J. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N. Engl. J. Med. 1995, 332, 1553-1559.
7. For recent reviews, see: (a) Cook, N. S.; Kottirsch, G.; Zerwes, H.-G. Platelet glycoprotein IIb/IIIa antagonists. Drugs Future 1994, 19, 135-159. (b) Weller, T.; Alig, L.; Hürzeler Müller, M.; Kouns, W. C.; Steiner, B. Fibrinogen receptor antagonists - a novel class of promising antithrombotics. Drugs Future 1994, 19, 461-476. (c) Austel, V.; Himmelsbach, F.; Müller, T. Non-peptidic fibrinogen receptor antagonists. Drugs Future 1994, 19, 757-764. (d) Lefkovits, J.; Plow, E. F.; Topol, E. J. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N. Engl. J. Med. 1995, 332, 1553-1559.
8. For recent reviews, see: (a) Cook, N. S.; Kottirsch, G.; Zerwes, H.-G. Platelet glycoprotein IIb/IIIa antagonists. Drugs Future 1994, 19, 135-159. (b) Weller, T.; Alig, L.; Hürzeler Müller, M.; Kouns, W. C.; Steiner, B. Fibrinogen receptor antagonists - a novel class of promising antithrombotics. Drugs Future 1994, 19, 461-476. (c) Austel, V.; Himmelsbach, F.; Müller, T. Non-peptidic fibrinogen receptor antagonists. Drugs Future 1994, 19, 757-764. (d) Lefkovits, J.; Plow, E. F.; Topol, E. J. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N. Engl. J. Med. 1995, 332, 1553-1559.
9. Coller, B. S.; Peerschke, E. I.; Scudder, L. E.; Sullivan, C. A. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoprotein IIb and/or IIIa. J. Clin. Invest. 1983, 72, 325-338.
10. Pidard, D.; Montgomery, R. R.; Bennett, J. S.; Kunicki, T. J. Interaction of AP-2, a monoclonal antibody specific for the human platelet glycoprotein IIb-IIIa complex with intact platelets. J. Biol. Chem. 1983, 258, 12582-12586.
11. Gould, R. J.; Polokoff, M. A.; Friedman, P. A.; Huang, T.-F.; Holt, J. C.; Cook, J. J.; Niewiarowski, S. Disintegrins: A family of integrin inhibitory proteins from viper venoms. Proc. Soc. Exp. Biol. Med. 1990, 195, 168-171.
12. Seymour, J. L.; Henzel, W. J.; Nevins, B.; Stults, J. T.; Lazarus, R. A. Decorsin, a potent glycoprotein IIb-IIIa antagonist and platelet aggregation inhibitor from the leech Macrobdella Decora. J. Biol. Chem. 1990, 265, 10143-10147.
13. (a) Samanen, J.; Ali, F.; Romoff, T.; Calvo, R.; Sorenson, E.; Vasko, J.; Storer, B.; Berry, D.; Bennett, D.; Strohsacker, M.; Powers, D.; Stadel, J.; Nichols, A. Development of a small RGD peptide fibrinogen receptor antagonist with potent antiaggregatory activity in vitro. J. Med. Chem. 1991, 34, 3114-3125.
14. (b) Ali, F. E.; Bennett, D. B.; Calvo, R. R.; Elliott, J. D.; Hwang, S. M.; Ku, T. W.; Lago, M. A.; Nichols, A. J.; Romoff, T. T; Shah, D. H.; Vasko, J. A.; Wong, A. S.; Yellin, T. O.; Yuan, C. K.; Samanen, J. M. Conformationally constrained peptides and semipeptides derived from RGD as potent inhibitors of the platelet fibrinogen receptor and platelet aggregation. J. Med. Chem. 1994, 37, 769-780.
15. Barker, P. L.; Bullens, S.; Bunting, S.; Burdick, D. J.; Chan, K. S.; Deisher, T.; Eigenbrot, C.; Gadek, T. R.; Gantzos, R.; Lipari, M. T.; Muir, C. D.; Napier, M. A.; Pitti, R. M.; Padua, A.; Quan, C.; Stanley, M.; Struble, M.; Tom, J. Y. K.; Burnier, J. P. Cyclic RGD peptide analogues as antiplatelet antithrombotics. J. Med. Chem. 1992, 35, 2040-2048.
16. (a) Zablocki, J. A.; Miyano, M.; Rao, S. N.; Panzer-Knodle, S.; Nicholson, N.; Feigen, L. Potent inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Asp-carboxylate of RGDX mimetics and the platelet GPIIb-IIIa receptor. J. Med. Chem. 1992, 35, 4914-4917.
17. (b) Zablocki, J. A.; Miyano, M.; Garland, R. B.; Pireh, D.; Schretzmann, L.; Rao, S. N.; Lindmark, R. J.; Panzer-Knodle, S.; Nicholson, N.; Taite, B.B.; Salyers, A. K.; King, L. W.; Campion, J. G.; Feigen, L. P. Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Arg-guanidine of RGDX mimetics and the platelet GPIIb-IIIa receptor. J. Med. Chem. 1993, 36, 1811-1819.
18. Jackson, S.; DeGrado, W. F.; Dwivedi, A.; Parthasarathy; A.; Higley, A.; Krywko, J.; Rockwell, A.; Markwalder, J.; Wells, G.; Wexler, R.; Mousa, S.; Harlow, R. L. Template-constrained cyclic peptides: design of high-affinity ligands for GPIIb/IIIa. J. Am. Chem. Soc. 1994, 116, 3220-3230.
19. Cheng, S.; Craig, W. S.; Mullen, D.; Tschopp, J. F.; Dixon, D.; Pierschbacher, M. D. Design and synthesis of novel cyclic RGD containing peptides as highly potent and selective integrin αIIbβ3 antagonists. J. Med. Chem. 1994, 37, 1-8.
20. Kloczewiak, M.; Timmons, S.; Bednarek, M. A.; Sakon, M.; Hawiger, J. Platelet receptor recognition domain on the γ chain of human fibrinogen and ist synthetic peptide analogues. Biochemistry 1989, 28, 2915-2919.
21. Alig, L.; Edenhofer, A.; Hadváry, P.; Hürzeler, M.; Knopp, D.; Müller, M.; Steiner, B.; Trezeciak, A.; Weller, T. Low molecular weight, non-peptide fibrinogen receptor antagonists. J. Med. Chem. 1992, 35, 4393-4407.
22. (a) Egbertson, M. S.; Chang, C. T.-C.; Duggan, M. E.; Gould, R. J.; Halczenko, W.; Hartmann, G. D.; Laswell, W. L.; Lynch, J. J., Jr.; Lynch, R. J.; Manno, P. D.; Naylor, A. M.; Prugh, J. D.; Ramjit, D. R.; Sitko, G. R.; Smith, R. S.; Turchi, L. M.; Zhang, G. Non-peptide fibrinogen receptor antagonists. 2. Optimisation of a tyrosine template as a mimic for Arg-Gly-Asp. J. Med. Chem. 1994, 37, 2537-2551.
23. (b) Barrett, J. S.; Murphy, G.; Peerlinck, K.; De Lepeleire, I.; Gould, R. J.; Panebianco, D.; Hand, E.; Deckmyn, H.; Vermylen, J.; Arnout, J. Pharmacokinetics and pharmaco-dynamics of MK-383, a selective non-peptide platelet glycoprotein IIb/IIIa receptor antagonist, in healthy men. Clin. Pharmacol. Ther. 1994, 56, 377-388.
24. (c) Egbertson, M. S.; Naylor, A. M.; Hartmann, G. D.; Cook, J. J.; Gould, R. J.; Holahan, M. A.; Lynch, J. J., Jr.; Lynch, R. J.; Stranieri, M. T.; Vassallo, L. M. Non-peptide fibrinogen receptor antagonists. 3. Design and discovery of a centrally constrained inhibitor. Bioorg. Med. Chem. Lett. 1994, 4, 1835-1840.
25. (d) Duggan, M. E.; Naylor-Olson, A. M.; Perkins, J. J.; Anderson, P. S.; Chang, C. T.-C.; Cook, J. J.; Gould, R. J.; Ihle, N. C.; Hartmann, G. D.; Lynch, J. J.; Lynch, R. J.; Manno, P. D.; Schaffer, L. W.; Smith, R. L. Non-peptide fibrinogen receptor antagonists. 3. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. J. Med. Chem. 1995, 38, 3332-3341.
26. (a) Ku, T. W.; Ali, F. E.; Barton, L. S.; Bean, J. W.; Bondinell, W. E.; Burgess, J. L.; Callahan, J. F.; Calvo, R. R.; Chen, L.; Eggleston, D. S.; Gleason, J. G.; Huffman, W. F.; Hwang, S. M.; Jakas, D. R.; Karash, C. B.; Keenan, R. M.; Kopple, K.D.; Miller, W. H.; Newlander, K. A.; Nichols, A.; Parker, M. F.; Peishoff, C. E.; Samanen, J. M.; Uzinskas, I.; Venslavsky, J. W. Direct design of a potent non-peptide fibrinogen receptor antagonist based on the structure and conformation of a highly constrained cyclic RGD peptide. J. Am. Chem. Soc. 1993, 115, 8861-8862.
27. (b) Ku, T. W.; Miller, W. H.; Bondinell, W. E.; Erhard, K. F.; Keenan, R. M.; Nichols, A. J.; Peishoff, C. E.; Samanen, J. M.; Wong, A. S.; Huffman, W. F. Potent non-peptide fibrinogen receptor antagonists which present an alternative pharmacophore. J. Med. Chem. 1995, 38, 9-12.
28. Eldred, C. D.; Evans, B.; Hindley, S,; Judkins, B. D.; Kelly, H. A.; Kitchin, J.; Lumley, P.; Porter, B.; Ross, B. C.; Smith, K. J.; Taylor, N. R.; Wheatcroft, J. R. Orally active non-peptide fibrinogen receptor (GPIIb/IIIa) antagonists: Identification of 4-[4-[4-(Aminoiminomethyl)phenyl)]-1-piperazinyl]-1-piperidineacetic acid as a long-acting, broad-spectrum antithrombotic agent. J. Med. Chem. 1994, 37, 3882-3885.
29. (a) Zablocki, J. A.; Tjoeng, F. S.; Bovy, P. R.; Miyano, M.; Garland, R. B.; Williams, K.; Schretzmann, L.; Zupec, M. E.; Rico, J. G.; Lindmark, R. J.; Toth, M.V.; McMackins, D. E.; Adams, S. P.; Panzer-Knodle, S. G.; Nicholson, N. S.; Taite, B. B.; Salyers, A. K.; King, L. W.; Campion, J. G.; Feigen, L. P. A novel series of orally active antiplatelet agents. Bioorg. Med. Chem. 1995, 3, 539-551.
30. (b) Anders, R. J.; Alexander, J. C.; Hantsbarger, G. L.; Burns, D. M.; Oliver, S. D.; Cole, G.; Fitzgerald, D. J.; Demonstration of potent inhibition of platelet aggregation with an orally active GPIIb/IIIa receptor antagonist. J. Am. Coll. Cardiol. 1995, 117A, abstr. 931-13.
31. Hoekstra, W. J.; Beavers, M. P.; Andrade-Gordon, P.; Evangelisto, M. F.; Keane, P. M.; Press, J. B.; Tomko, K. A.; Fan, F.; Kloczewiak, M.; Mayo, K. H.; Durkin, K. A.; Liotta, D. C. Design and evaluation of nonpeptide fibrinogen γ-chain based GPIIb/ IIIa antagonists. J. Med. Chem. 1995, 38, 1582-1592.
32. The EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N. Engl. J. Med. 1994, 330, 956-961.
33. Incorporation of a methyl group into the structure of 2 at the 4 position of the hydantoin ring increased the potency by not more than a factor of 2, suggesting that the methyl group by itself is not the major cause for the strong increase in potency of 3 compared to 2.
34. Marguerie, G. A.; Plow, E. F.; Edgington, T. S. Human platelets possess an inducible and saturable receptor specific for fibrinogen. J. Biol. Chem. 1979, 254, 5357-5363.
35. (a) Nachman, R. L.; Leung, L. L. K. Complex formation of platelet membrane glycoproteins IIb and IIIa with fibrinogen. J. Clin. Invest. 1982, 69, 263-269.
36. 3 and glycoprotein iib-IIIa with fibrinogen: Differential peptide recognition accounts distinct binding sites. J. Biol. Chem. 1990, 265, 12267-12271.
37. (c) Charo, I. F.; Nannizzi, L.; Phillips, D. R.; Hsu, M. A.; Scarborough, R. M. Inhibition of fibrinogen binding to GP iib-IIIa by a GP Iiia peptide. J. Biol. Chem. 1991, 266, 1415-1421.
38. (d) Scarborough, R. M.; Rose J. W.; Hsu, M. A.; Phillips, D. R.; Fried, V. A.; Campbell, A. M.; Nannizzi, L.; Charo, I. F. Barbourin - a GP IIb-IIIa-specific integrin antagonist from the venom of SISTRURUS M. BARBOURI. J. Biol Chem. 1991, 266, 9359-9362.
39. (a) Ruggeri, Z. M.; De Marco, L.; Gatti, L.; Bader, R.; Montgomery, R. R. Platelets have more than one binding site for von Willebrand factor. J. Clin. Invest. 1983, 72, 1-12.
40. (b) Pietu, G.; Cherel, G.; Marguerie, G.; Meyer, D. Inhibition of von Willebrand factor - platelet interaction by fibrinogen. Nature 1984, 308, 648-649.
41. Just, M.; Hropot, M.; Jablonka, B.; König, W.; Stilz, H. U. Biological Characteristics of the New Orally Active Fibrinogen Receptor Antagonist-S 1762. Thrombosis Haemostasis 1995, 73, 1444.
42. Bucherer, H. T.; Lieb, V. A. Über die Bildung substituierter Hydantoine aus Aldehyden und Ketonen. (Formation of substituted Hydantoins from Aldehydes and Ketones.) J. Prakt. Chem. 1934, 141, 5-43.
43. Ellis, G. P.; Romney-Alexander, T. M. Cyanation of Aromatic Halides. Chem. Rev. 1987, 87, 779-794.
44. Pinner, A. Die Imidoäther und ihre Derivate (The Imidoethers and their Derivatives); Oppenheim: Berlin, 1892.